The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment |
| |
| Authors: | A J Bradbury B Costall P G Jenner M E Kelly C D Marsden R J Naylor |
| |
| Institution: | 1. Postgraduate School of Studies in Pharmacology, University of Bradford, Bradford, BD7 1DP U.K.;2. M.R.C. Movement Disorder Research Group, University Department of Neurology and Parkinson''s Disease Society Research Centre, Institute of Psychiatry and King''s College Hospital Medical School, Denmark Hill, London SE5 8AF U.K. |
| |
| Abstract: | 1-Methyl-4-phenylpyridine (MPP+) injected into the cerebral ventricles (ICV) of mouse caused depletions of striatal dopamine (DA)(-42%), 3,4-dihydroxyphenylacetic acid (DOPAC) (-34%) and homovanillic acid (HVA) (-16%) content without significant reductions in levels of noradrenaline (NA), serotonin (5-HT) or 5-hydroxyindoleacetic acid (5-HIAA). When deprenyl was administered before MPP+, striatal DA and its metabolites were further depleted, and striatal NA and 5-HT levels also were reduced. Further, whilst ICV MPP+ alone failed to influence the biochemistry of the limbic areas (nucleus accumbens plus tuberculum olfactorium), in the presence of deprenyl MPP+ caused 20-40% reductions in levels of limbic NA, DA, DOPAC, HVA, 5-HT and 5-HIAA. Therefore, deprenyl treatment does not prevent the neurotoxic actions of MPP+; indeed, a more extensive neurotoxicity for MPP+ is revealed in the presence of this monoamine oxidase inhibitor. |
| |
| Keywords: | neurotoxicity striatum limbic system deprenyl |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
